Stroke, Vol 16, 406-415, Copyright © 1985 by American Heart Association
The Persantine Aspirin Trial focused on the question of whether the
administration of the combination of aspirin and dipyridamole (Persantine)
would result in a lower incidence of cerebral or retinal infarction or
death than the administration of aspirin alone for persons with a history
of recent carotid territory transient ischemic attacks (TIAs). Fifteen
centers in the United States and Canada participated and 890 individuals
were admitted and randomly allocated to either aspirin (325 mg) plus
placebo or aspirin (325 mg) plus Persantine (75 mg) four times daily.
Ninety eight percent of the subjects were followed for at least one year;
many were followed for four to five years. The results of life table
analysis indicate that the overall endpoint rates for the "aspirin only"
and "aspirin plus Persantine" groups are identical. Thus, for TIA patients
taking aspirin, the addition of Persantine contributes nothing. There was a
clustering of stroke endpoints during the first month after randomization.
Deaths from all causes were essentially equally divided between the two
treatment groups.
ARTICLES
Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group
This article has been cited by other articles:
 |
|
 |
|
  G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Thijs, R. Lemmens, and S. Fieuws Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke Eur. Heart J., May 1, 2008; 29(9): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review Stroke, May 1, 2008; 39(5): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Verro, P. B. Gorelick, and D. Nguyen Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis Stroke, April 1, 2008; 39(4): 1358 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Liao Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer? Circulation, March 27, 2007; 115(12): 1615 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-C. Diener How Much Esprit Is in ESPRIT? Stroke, November 1, 2006; 37(11): 2856 - 2857. [Full Text] [PDF]
|
|
|
|
|
|
E. Touze, O. Varenne, G. Chatellier, S. Peyrard, P. M. Rothwell, and J.-L. Mas Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic Stroke: A Systematic Review and Meta-Analysis Stroke, December 1, 2005; 36(12): 2748 - 2755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Leonardi-Bee, P. M.W. Bath, M.-G. Bousser, A. Davalos, H.-C. Diener, B. Guiraud-Chaumeil, J. Sivenius, F. Yatsu, M. E. Dewey, and on behalf of the Dipyridamole in Stroke Collaborat Dipyridamole for Preventing Recurrent Ischemic Stroke and Other Vascular Events: A Meta-Analysis of Individual Patient Data From Randomized Controlled Trials Stroke, January 1, 2005; 36(1): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tran and S. S. Anand Oral Antiplatelet Therapy in Cerebrovascular Disease, Coronary Artery Disease, and Peripheral Arterial Disease JAMA, October 20, 2004; 292(15): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eliasziw, J. Kennedy, M. D. Hill, A. M. Buchan, and H. J.M. Barnett Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease Can. Med. Assoc. J., March 30, 2004; 170(7): 1105 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E.L.L.M. De Schryver, A. Algra, and J. van Gijn Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease Stroke, August 1, 2003; 34(8): 2072 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Matias-Guiu, J. M. Ferro, J. Alvarez-Sabin, F. Torres, M. D. Jimenez, A. Lago, T. Melo, and D. C. Tong Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction: The TACIP Study: A Randomized, Double-Blind, Multicenter Trial * Can Aspirin Ever Be Surpassed for Stroke Prevention? Stroke, April 1, 2003; 34(4): 840 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L R CAPLAN Evidence based medicine: concerns of a clinical neurologist J. Neurol. Neurosurg. Psychiatry, November 1, 2001; 71(5): 569 - 574. [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Sacco and M. S. Elkind Update on Antiplatelet Therapy for Stroke Prevention Arch Intern Med, June 12, 2000; 160(11): 1579 - 1582. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Albers, R. G. Hart, H. L. Lutsep, D. W. Newell, and R. L. Sacco Supplement to the Guidelines for the Management of Transient Ischemic Attacks : A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association Stroke, November 1, 1999; 30(11): 2502 - 2511. [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Wilterdink and J. D. Easton Dipyridamole Plus Aspirin in Cerebrovascular Disease Arch Neurol, September 1, 1999; 56(9): 1087 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A ALGRA, J VAN GIJN, A ALGRA, and P J KOUDSTAAL Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone? J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 557 - 559. [Full Text]
|
|
|
|
|
|
J. He, P. K. Whelton, B. Vu, and M. J. Klag Aspirin and Risk of Hemorrhagic Stroke: A Meta-analysis of Randomized Controlled Trials JAMA, December 9, 1998; 280(22): 1930 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Managing carotid stenosis DTB, February 1, 1998; 36(2): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.J.M. Barnett, M. Kaste, H. Meldrum, and M. Eliasziw Aspirin Dose in Stroke Prevention : Beautiful Hypotheses Slain by Ugly Facts Stroke, April 1, 1996; 27(4): 588 - 592. [Full Text]
|
|
|
|
 |
|
 S. Maruyama, S. Uchiyama, H. Tohgi, S. Hirai, Y. Ikeda, Y. Shinohara, T. Matsuda, M. Fujishima, and M. Kameyama A Randomized Trial of E5510 versus Aspirin in Patients with Transient Ischemic Attacks: The Japanese E5510 TIA Study-1 (JETS-1) Group Angiology, November 1, 1995; 46(11): 999 - 1008. [Abstract] [PDF]
|
|
|
|
 |
|
 H. J.M. Barnett, M. Eliasziw, and H. E. Meldrum Drugs and Surgery in the Prevention of Ischemic Stroke N. Engl. J. Med., January 26, 1995; 332(4): 238 - 248. [Full Text] [PDF]
|
|
|
|
|
|
W. S. Moore, H.J.M. Barnett, H. G. Beebe, E. F. Bernstein, B. J. Brener, T. Brott, L. R. Caplan, A. Day, J. Goldstone, R. W. Hobson II, et al. Guidelines for Carotid Endarterectomy : A Multidisciplinary Consensus Statement From the Ad Hoc Committee, American Heart Association Circulation, January 15, 1995; 91(2): 566 - 579. [Abstract] [Full Text]
|
|
|
|
|
|
W. S. Moore, H.J.M. Barnett, H. G. Beebe, E. F. Bernstein, B. J. Brener, T. Brott, L. R. Caplan, A. Day, J. Goldstone, R. W. Hobson II, et al. Guidelines for Carotid Endarterectomy : A Multidisciplinary Consensus Statement From the Ad Hoc Committee, American Heart Association Stroke, January 1, 1995; 26(1): 188 - 201. [Abstract] [Full Text]
|
|
|
|
 |
|
 Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]
|
|
|
|
|
|
W. R. Slade JR., S. Raguthu, R. Borras, J.R. Chen, and A. Alperovich T.I.A. Revisited: New Wine Old Bottle Angiology, May 1, 1986; 37(5): 365 - 371. [Abstract] [PDF]
|
|